KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $2.3 billion.

  • Jazz Pharmaceuticals' Total Current Liabilities rose 120.79% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 120.79%. This contributed to the annual value of $1.0 billion for FY2024, which is 32.42% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Total Current Liabilities of $2.3 billion as of Q3 2025, which was up 9.80% from $2.1 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Total Current Liabilities high stood at $2.3 billion for Q3 2025, and its period low was $705.4 million during Q2 2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $1.5 billion (2023), whereas its average is $1.4 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Total Current Liabilities crashed by 34.54% in 2024, and later soared by 120.79% in 2025.
  • Jazz Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $809.3 million in 2021, then climbed by 15.31% to $933.2 million in 2022, then soared by 64.67% to $1.5 billion in 2023, then plummeted by 32.42% to $1.0 billion in 2024, then skyrocketed by 120.79% to $2.3 billion in 2025.
  • Its Total Current Liabilities was $2.3 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $1.2 billion in Q1 2025.